Inspire Medical Systems (INSP) PT Raised to $252 at Baird

Baird analyst David Rescott raised the price target on Inspire Medical Systems (NYSE: INSP) to $252.00 (from $240.00) while maintaining a Outperform rating.

The analyst commented: "INSP remains a best-in-class idea after the company delivered another revenue/EPS beat/raise with +33% revenue growth, 7% OM, and confirmed FY25 CNS revenue growth estimates (+19-20% Y/Y). With INSP V full launch approaching (early-2025) and ongoing international expansion layering in, we think FY25 should be another year of continued upside to INSP's best-in-class growth profile. Add in ongoing margin improvements as DTC levels and related-ROI improves, we think INSP could be on track to achieve ~9-10% OM by 2026E (on high-teens revenue growth), supporting expansion to INSP's already premium multiple."

You May Also Be Interested In

• York Space Systems (YSS) PT Lowered to $15 at Jefferies
• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• Indaptus Therapeutics (INDP) files for 59M share offering by selling stockholders